Circulating Tumor DNA

NCT06923527 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

ER+ Breast Cancer

Interventions

DRUG: Elacestrant

Sponsor

Yale University

Collaborators

[object Object]
[object Object]